ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.

Results of the PRECISION study are embraced by some and soundly criticized by others. What would you tell your osteoarthritis patients?

©Orhan Cam/Shutterstock.com

This week, President-elect Donald Trump announced his picks to head Health and Human Services and CMS. Plus, the 21st Century Cures Act passes the House.

©maya2008/Shutterstock.com

Implantable cardiac monitoring devices now detect "silent" AF. But now that we "hear" it, what should we do?

©Irina Braga/Shutterstock.com

In order for there to be a "Cancer Moonshot," healthcare needs to see advancements in the operational side of the industry, too.

How one institution’s initiative improved patient history reporting, from RSNA 2016.

Gentle reader, the hour is late. As the poet said, almost all of the grains of sand allotted to 2016 have sifted down onto the pyramid of memory. Before this year’s hourglass empties, though, let’s take a moment to reflect on some of the phenomena we observed during the past months in this esoteric branch of medicine.

The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.

©Lightspring/Shutterstock.com

A signal for increased risk of hemorrhage when the NOAC is coadministered with 2 statins comes as a surprise to some.

Pages

Subscribe to Cancer Network RSS

By clicking Accept, you agree to become a member of the UBM Medica Community.